Orphan disease firm Hyperion Therapeutics Inc. priced its initial public offering (IPO), shaving the price from the midpoint of $12 per share cited in its amended S-1 filing earlier this month to $10 per share – $1 below the proposed range – but upsizing the offering from 4.2 million to 5 million shares.
Sarepta Therapeutics Inc. (formerly AVI BioPharma Inc.) wowed clinicians and investors Tuesday with Phase IIb findings for its exon-skipping compound, eteplirsen, in Duchenne's muscular dystrophy (DMD).
Regenerative medicine developer Histogenics Corp. said Tuesday that it completed a $49 million financing to complete its ongoing Phase III program for lead candidate NeoCart, an autologous neocartilage tissue implant that utilizes a patient's own cells to regenerate articular cartilage in the knee. The trial is currently enrolling patients.
Amicus Therapeutics Inc. strengthened ties with partner GlaxoSmithKline plc to develop and commercialize its lead compound, the chaperone migalastat HC1 (Amigal), in Fabry disease.
Scientists have long been fascinated by curcumin, a naturally occurring chemical found in the root of turmeric, a plant known as Curcuma longa. The compound is known to have antioxidant and anti-inflammatory properties, but traditional use has been limited to topical and gastrointestinal indications because oral bioavailability is negligible.
Orphan Synergy Europe (OSE) Pharma SA came out of the starting gate with a Phase II candidate, in-licensing a therapeutic cancer vaccine discovered at San Diego-based Epimmune Inc. that had languished following that company's 2005 merger with Immuno-Designed Molecules (IDM) SA, of Paris.
After mulling its options for three months, Human Genome Sciences Inc. accepted a sweetened proposal from GlaxoSmithKline plc, agreeing to a union that most industry observers expected all along.
Celgene International Sàrl, the Boudry, Switzerland, subsidiary of Celgene Corp., reported positive top-line results for apremilast, an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), in patients with psoriatic arthritis (PsA) who had received an oral disease-modifying antirheumatic drug (DMARD) or biologic therapy or had failed on an anti-tumor necrosis factor (TNF) agent.
Orphan Synergy Europe (OSE) Pharma SA came out of the starting gate with a Phase II candidate, in-licensing a therapeutic cancer vaccine discovered at San Diego-based Epimmune Inc. that had languished following that company's 2005 merger with Immuno-Designed Molecules (IDM) SA, of Paris.
